The purpose of this study is to look at the effectiveness of a combination of treatments, polatuzumab vedotin with rituximab, gemcitabine, dexamethasone, and cisplatin (PV-RGDP) at treating relapsed or refractory diffuse large B-cell lymphoma.
COM_RESEARCHSTUDIES_DETAIL_HEADER_BASIC_CONTACT_4
United States (Nationwide)
Christopher Dittus
Lineberger Comprehensive Cancer Center
Clinical or Medical
Interventional
Cancer (Lymphoma)
22-1663
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
